| Literature DB >> 32753967 |
Wei Dong1,2, Hua Yu1,2, Yu-Yao Zhu1,2, Zhi-Hong Xian1,2, Jia Chen1,2, Hao Wang3, Chun-Chao Shi4, Guang-Zhi Jin5, Hui Dong1,2, Wen-Ming Cong1,2.
Abstract
PURPOSE: This study aimed to propose an effective quantitative pathological scoring system and to establish nomogram to assess the stage of cirrhosis and predict postoperative survival of hepatocellular carcinoma (HCC) with cirrhosis patients after hepatectomy.Entities:
Keywords: HCC; cirrhosis; hepatocellular carcinoma; nomogram; pathology; scoring system
Year: 2020 PMID: 32753967 PMCID: PMC7354953 DOI: 10.2147/CMAR.S223417
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
The New Cirrhosis Scoring System
| Variables | Grade | ||
|---|---|---|---|
| 1 | 2 | 3 | |
| NICP | ≤1102 | 1102<G1≤2519 | >2519 |
| RFA | ≤0.1192 | 0.1192<G2≤0.2040 | >0.2040 |
| DPL (/cm2) | ≤13.13 | 13.13<G3≤23.67 | >23.67 |
| MRP14 (/mm2) | ≤113.4 | 113.4<G4≤185.5 | >185.5 |
| New Cirrhosis System Score=OR1G(NICP)-1+OR2G(RFA)-1+OR3G(DPL)-1+OR4G(MRP14)-1 | |||
| (New Cirrhosis System Score=3.27G(NICP)-1 +3.07 G(RFA)-1 +2.31 G(DPL)-1 +3.32 G(MRP14)-1) | |||
| System Grade: I≤6.85, 6.85<II≤24.15, IV>24.15 | |||
Notes: OR1, OR value of NICP; OR2, OR value of RFA; OR3, OR value of DPL; OR4, OR value of MRP14; G(NICP), grade of NICP; G(RFA), grade of RFA; G(DPL), grade of DPL; G(MRP14), grade of MRP14.
Figure 1Four histological items for evaluation of cirrhosis system. H&E stain shows NICP of Cirrhosis Stage 1 (A), Cirrhosis Stage 2 (B), Cirrhosis Stage 3 (C) (F); Masson stain shows RFA of Cirrhosis Stage 1 (D), Cirrhosis Stage 2 (E), Cirrhosis Stage 3 (F), DPL of Cirrhosis Stage 1 (G), Cirrhosis Stage 2 (H), Cirrhosis Stage 3 (I); MRP14 stain shows of Cirrhosis Stage 1 (J), Cirrhosis Stage 2 (K), Cirrhosis Stage 3 (L). Black boxes, representative views of tissue; green boxes, enlarged representative views.
Figure 2Kaplan–Meier survival curves of OS differences among patients in combination of training and testing group. Cirrhosis stage of training group (A) and testing group (B), Laennec stage of training group (C), and testing group (D).
Univariate and Multivariate Analyses of Factors Associated with OS in Combined Training and Testing Cohorts
| Factors | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% Cl | P-value | HR | 95% Cl | P-value | |
| Age: years | 1.025 | 1.005–1.046 | ||||
| Sex: male vs female | 0.910 | 0.536–1.545 | 0.727 | |||
| Tumor Size: cm | 1.111 | 1.066–1.157 | ||||
| Tumor Number: Single vs Multiple | 0.599 | 0.406–0.884 | ||||
| Serum AFP, μg/L | 1.001 | 1.000–1.001 | 1.000 | 1.000–1.001 | ||
| Serum CEA, μg/L | 1.062 | 1.027–1.098 | ||||
| Serum CA 19–9, U/mL | 1.005 | 1.000–1.011 | 0.066 | |||
| Serum TBIL, μmol/L | 1.007 | 0.997–1.016 | 0.188 | |||
| Serum ALB, g/L | 0.962 | 0.923–1.004 | 0.076 | |||
| Serum ALT, U/L | 1.000 | 0.997–1.002 | 0.776 | |||
| Serum AST, U/L | 1.000 | 0.997–1.002 | 0.928 | |||
| Serum GGT, U/L | 1.003 | 1.002–1.004 | ||||
| Serum ALP, U/L | 1.008 | 1.004–1.011 | ||||
| Serum PLT, ×109/L | 0.996 | 0.993–1.000 | ||||
| Serum PT, S | 1.217 | 1.061–1.395 | ||||
| Serum Cre, μmol/L | 1.005 | 0.998–1.012 | 0.192 | |||
| Micro-vascular invasion: no vs yes | 0.662 | 0.454–0.965 | 1.613 | 1.006–2.585 | ||
| Laennec Score | 1.763 | 1.401–2.218 | ||||
| TNM: I vs II vs III vs IV | 1.656 | 1.360–2.016 | 1.540 | 1.201–1.975 | ||
| New Cirrhosis Score | 1.079 | 1.062–1.095 | 1.072 | 1.054–1.090 | ||
Notes: TNM, cancer tumor-node-metastasis classification system; statistically significant values are bold.
Abbreviations: OS, overall survival; Cl, confidence interval; AFP, preoperative level of serum α-fetoprotein; CEA, preoperative level of serum carcinoembryonic antigen; CA19-9, preoperative level of serum cancer antigen 19-9.
Figure 3HCC with cirrhosis survival nomogram. (To use the nomogram, an individual patient’s value is located on each variable axis, and a line is drawn upward to determine the number of points received for each variable value. The sum of these numbers is located on the Total Points axis, and a line is drawn downward to the survival axes to determine the likelihood of 1-, 3-, or 5-year survival). MVI, microvascular invasion.
Figure 4The calibration curve for predicting patient survival at (A) 1 year, (B) 3 years, and (C) 5 years in combined training and testing cohort. Nomogram-predicted probability of overall survival is plotted on the x-axis; actual overall survival is plotted on the y-axis.